VYNE Therapeutics Faces Delisting Concerns

TL;DR

VYNE's on notice for delisting - stock status in jeopardy.

AI Summary

VYNE Therapeutics Inc. filed an 8-K on September 12, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The filing indicates a significant event related to the company's stock exchange status as of September 11, 2025.

Why It Matters

This filing signals potential issues with VYNE Therapeutics' ability to remain listed on its current stock exchange, which could impact liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading and market valuation.

Key Players & Entities

• VYNE Therapeutics Inc. (company) — Registrant
• September 11, 2025 (date) — Earliest event reported
• September 12, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar
• $1.00 — maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listi
• $1 million — stock split if necessary, and meets the $1 million market value of publicly held shares re

Filing Documents

• tm2525917d1_8k.htm (8-K) — 25KB
• 0001104659-25-089531.txt ( ) — 188KB
• vyne-20250911.xsd (EX-101.SCH) — 3KB
• vyne-20250911_lab.xml (EX-101.LAB) — 33KB
• vyne-20250911_pre.xml (EX-101.PRE) — 22KB
• tm2525917d1_8k_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 11, 2025, VYNE Therapeutics Inc. (the "Company") received notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock (the "Common Stock") was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company's Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until March 10, 2026, to regain compliance with the minimum bid price requirement. During this period, the Company's Common Stock will continue to trade on the Nasdaq Capital Market. If at any time before March 10, 2026, the bid price of the Company's Common Stock closes at or above $1.00 per share for a minimum of ten consecutive trading days, Nasdaq will provide written notification that the Company has achieved compliance with this minimum bid price requirement. The Company is considering all available options to regain compliance with the listing rule. However, there can be no assurance that the Company will be able to regain compliance with the rule or will otherwise be in compliance with other Nasdaq listing criteria. In the event the Company does not regain compliance by March 10, 2026, a second 180-day compliance period may be available if the Company provides written notice to Nasdaq that it intends to regain compliance with the bid price requirement during the second 180-day compliance period, by effecting a reverse stock split if necessary, and meets the $1 million market value of publicly held shares requirement for continued listing and all other initial inclusion

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC . Date: September 12, 2025 By: /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel 2

View Full Filing

View this 8-K filing on SEC EDGAR